Print
Email
Print Edition StoriesWednesday, April 16, 2008
Paratek caps $40M funding to launch Phase 3 trial
Paratek Pharmaceuticals Inc. reports it has completed a $40 million financing to begin a Phase 3 clinical trial of an antibiotic to treat serious infections.
The Boston-based biotech firm has now raised $134 million. The company announced the first tranche of the latest $40 million round in October 2007.
New York-based firm Aisling Capital led the round, which included new investors DE Shaw and Boston Life Science Venture Corp.
Previous investors Nomura Phase4 Ventures, Novartis BioVentures, BioFund Ventures, HBM BioVentures, Lombard Odier Darier Hentsch, BioVeda Fund and Hercules Technology Growth Capital also contributed.
Privately held Paratek said it recently completed a Phase 2 clinical study of its lead antibiotic, PTK 0796, as a treatment for potentially fatal infections such as skin infections and pneumonia that require hospitals stays.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
